Liver disease and the renin-angiotensin system: Recent discoveries and clinical implications

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 9, 2008, Pages 1327-1338

  Lubel, John S ^b   Herath, Chandana B ^b   Burrell, Louise M ^b   Angus, Peter W ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin (Ang) (1 7); Angiotensin converting enzyme 2; Hepatic fibrosis; Renin angiotensin system

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPTAPEPTIDE; IRBESARTAN; KALLIKREIN; KININ; LOSARTAN; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; OLMESARTAN; PERINDOPRIL; PLACEBO; PROPRANOLOL; RENIN; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG RECEPTOR BINDING; FLUID BALANCE; HEART MUSCLE FIBROSIS; HEPATITIS C; HUMAN; KIDNEY FIBROSIS; LIVER DISEASE; LIVER FIBROSIS; MONOTHERAPY; PLASMA RENIN ACTIVITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM BALANCE; TISSUE INJURY; VASCULAR RESISTANCE;

EID: 49849093788     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05461.x     Document Type: Review

References (119)

1. Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT. Purification and properties of angiotensin-converting enzyme from hog lung. Circ. Res. 1972 31 : 356 66.
2. Skeggs LT, Lentz KE, Gould AB, Hochstrasser H, Kahn JR. Biochemistry and kinetics of the renin-angiotensin system. Fed. Proc. 1967 26 : 42 7.
3. Johnston CI. Franz Volhard Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J. Hypertens. Suppl. 1992 10 : S13 26.
4. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991 351 : 233 6.
5. Sasaki K, Yamano Y, Bardhan S et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991 351 : 230 3.
6. Kambayashi Y, Bardhan S, Takahashi K et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993 268 : 24 543 6.
7. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. 2000 52 : 639 72.
8. Timmermans PB, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am. J. Hypertens. 1992 5 (Pt 2 S221 35.
9. Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr. Opin. Nephrol. Hypertens. 1997 6 : 28 34.
10. von Bohlen und Halbach O. Angiotensin IV in the central nervous system. Cell. Tissue Res. 2003 311 : 1 9.
11. Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, Ferrario CM. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc. Natl Acad. Sci. USA 1988 85 : 4095 8.
12. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000 87 : E1 9.
13. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000 275 : 33 238 43.
14. Santos RA, Simoes e Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl Acad. Sci. USA 2003 100 : 8258 63.
15. Lambert DW, Yarski M, Warner FJ et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 2005 280 : 30113 19.
16. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol. Metab. 2004 15 : 166 9.
17. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. 2004 383 (Pt 1 45 51.
18. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002 277 : 14 838 43.
19. Li W, Moore MJ, Vasilieva N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003 426 : 450 4.
20. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am. J. Physiol. 1995 269 (Pt 2 H313 19.
21. Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001 38 (Pt 2 665 8.
22. Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Braz. J. Med. Biol. Res. 2002 35 : 1083 90.
23. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996 28 : 104 8.
24. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H1560 6.
25. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999 33 (Pt 2 207 11.
26. Iwata M, Cowling RT, Gurantz D et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H2356 63.
27. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am. J. Physiol. Heart Circ. Physiol. 2006 290 : H2417 23.
28. Kucharewicz I, Pawlak R, Matys T, Pawlak D, Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002 40 : 774 9.
29. Kucharewicz I, Chabielska E, Pawlak D, Matys T, Rolkowski R, Buczko W. The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan. J. Renin Angiotensin Aldosterone Syst. 2000 1 : 268 72.
30. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 2006 28 : 702 707.
31. Tom B, Dendorfer A, Danser AH. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?. Int. J. Biochem. Cell Biol. 2003 35 : 792 801.
32. Gioli-Pereira L, Nascimento EA, Santos EL et al. Fate of bradykinin on the rat liver when administered by the venous or arterial route. J. Gastroenterol. Hepatol. 2005 20 : 463 73.
33. Gorelik G, Carbini LA, Scicli AG. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J. Pharmacol. Exp. Ther. 1998 286 : 403 10.
34. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997 29 (Pt 2 394 400.
35. Bataller R, Sancho-Bru P, Gines P et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003 125 : 117 25.
36. Leung PS, Chappell MC. A local pancreatic renin-angiotensin system: endocrine and exocrine roles. Int. J. Biochem. Cell Biol. 2003 35 : 838 46.
37. Herath CB, Warner FJ, Lubel JS et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J. Hepatol. 2007 47 : 387 95.
38. Paizis G, Tikellis C, Cooper ME et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005 54 : 1790 6.
39. Lubel JS, Angus PW. Modern management of portal hypertension. Intern. Med. J. 2005 35 : 45 9.
40. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 2001 21 : 437 51.
41. Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem. Biophys. Res. Commun. 2003 308 : 177 83.
42. Nabeshima Y, Tazuma S, Kanno K et al. Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem. Biophys. Res. Commun. 2006 346 : 658 64.
43. Jonsson JR, Clouston AD, Ando Y et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001 121 : 148 55.
44. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol. 2003 139 : 1085 94.
45. Li X, Meng Y, Yang XS, Mi LF, Cai SX. ACEI attenuates the progression of CCl4-induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP-2,9. World J. Gastroenterol. 2005 11 : 4807 11.
46. Ohishi T, Saito H, Tsusaka K et al. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol. Res. 2001 21 : 147 58.
47. Paizis G, Gilbert RE, Cooper ME et al. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J. Hepatol. 2001 35 : 376 85.
48. Ramos SG, Montenegro AP, Goissis G, Rossi MA. Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. Pathol. Int. 1994 44 : 655 61.
49. Tuncer I, Ozbek H, Ugras S, Bayram I. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp. Toxicol. Pathol. 2003 55 : 159 66.
50. Wei HS, Li DG, Lu HM et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). World J. Gastroenterol. 2000 6 : 540 5.
51. Wei HS, Lu HM, Li DG et al. The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl(4). World J. Gastroenterol. 2000 6 : 824 8.
52. Yoshiji H, Yoshii J, Ikenaka Y et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J. Hepatol. 2002 37 : 22 30.
53. Ramalho LN, Ramalho FS, Zucoloto S et al. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 2002 49 : 1499 502.
54. Ibanez P, Solis N, Pizarro M et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2007 22 : 846 51.
55. Hirose A, Ono M, Saibara T et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007 45 : 1375 81.
56. Sookoian S, Fernandez MA, Castano G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J. Gastroenterol. 2005 11 : 7560 3.
57. Debernardi-Venon W, Martini S, Biasi F et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J. Hepatol. 2007 46 : 1026 33.
58. Terui Y, Saito T, Watanabe H et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002 36 (Pt 1 1022.
59. Yoshiji H, Noguchi R, Fukui H. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J. Gastroenterol. 2005 40 : 215 16.
60. Rimola A, Londono MC, Guevara G et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004 78 : 686 91.
61. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 : 1222 5.
62. Yokohama S, Tokusashi Y, Nakamura K et al. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J. Gastroenterol. 2006 12 : 322 6.
63. Roskams T, Desmet VJ, Verslype C. Development, structure and function of the liver. In : Burt AD, Portmann BC, Ferrell LD, eds. Macsween's Pathology Of The Liver, Fifth edn. Edinburgh : Churchill Livingstone, 2007.
64. Feu F, Garcia-Pagan JC, Bosch J et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995 346 : 1056 9.
65. Bataller R, Gines P, Nicolas JM et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000 118 : 1149 56.
66. Herath CB, Warner FJ, Lubel JS et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J. Hepatol. 2007 47 : 387 95.
67. Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 2000 118 : 1261 5.
68. Ballet F, Chretien Y, Rey C, Poupon R. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J. Pharmacol. Exp. Ther. 1988 244 : 283 9.
69. Croquet V, Moal F, Veal N et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J. Hepatol. 2002 37 : 773 80.
70. Vlachogiannakos J, Tang AK, Patch D, Burroughs AK. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001 49 : 303 8.
71. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999 29 : 334 9.
72. Gonzalez-Abraldes J, Albillos A, Banares R et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001 121 : 382 8.
73. Tripathi D, Therapondos G, Lui HF, Johnston N, Webb DJ, Hayes PC. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am. J. Gastroenterol. 2004 99 : 390 4.
74. Schepke M, Werner E, Biecker E et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001 121 : 389 95.
75. Zhang Z, Feng H, Leng X, Ma F, Wang B, Du R. The levels of renin activity, angiotensin converting enzyme and angiotensin II in cirrhotic patients with ascites undergoing portacaval shunt Zhonghua Wai Ke Za Zhi 1999 37 : 366 8.
76. Daskalopoulos G, Pinzani M, Murray N, Hirschberg R, Zipser RD. Effects of captopril on renal function in patients with cirrhosis and ascites. J. Hepatol. 1987 4 : 330 6.
77. Pariente EA, Bataille C, Bercoff E, Lebrec D. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 1985 88 (Pt 1 1255 9.
78. Wagatsuma Y, Naritaka Y, Shimakawa T et al. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy. Hepatogastroenterology 2006 53 : 171 4.
79. Eriksson LS, Kagedal B, Wahren J. Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis. Am. J. Med. 1984 76 : 66 70.
80. Baik SK, Park DH, Kim MY et al. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity. J. Gastroenterol. 2003 38 : 1150 4.
81. Chiang HT, Cheng JS, Lin M, Tseng WS, Chang JM, Lai KH. Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis. J. Gastroenterol. Hepatol. 1995 10 : 256 60.
82. Svoboda P, Ochmann J, Kantorova I. Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension. Hepatogastroenterology 1992 39 : 549 52.
83. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin- converting enzyme 2, and neprilysin in a family study. Hypertension 2006 48 : 914 20.
84. Sookoian S, Castano G, Garcia SI, Viudez P, Gonzalez C, Pirola CJ. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am. J. Gastroenterol. 2005 100 : 636 42.
85. Komeda K, Jin D, Takai S et al. Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis. Hepatol. Res. 2007.
86. Shimizu S, Satomura K, Aramaki T, Katsuta Y, Takano T, Omoto Y. Hepatic chymase level in chronic hepatitis: co-localization of chymase with fibrosis. Hepatol. Res. 2003 27 : 62 6.
87. Campbell DJ. Renin-angiotensin system inhibition: how much is too much of a good thing?. Intern. Med. J. 2002 32 : 616 20.
88. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin. Exp. Pharmacol. Physiol. Suppl. 1996 3 : S125 31.
89. Arroyo V, Bosch J, Mauri M et al. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur. J. Clin. Invest. 1979 9 : 69 73.
90. Bosch J, Arroyo V, Betriu A et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980 78 : 92 9.
91. Sakata T, Takenaga N, Endoh T, Wada O, Matsuki K. Diagnostic significance of serum angiotensin-converting enzyme activity in biochemical tests with special reference of chronic liver diseases. Jpn. J. Med. 1991 30 : 402 7.
92. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs? Clin. Sci. (Lond.) 2007 113 : 109 18.
93. Pereira RM, Dos Santos RA et al. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin. J. Hepatol. 2006 1 7.
94. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 1998 31 (Pt 2 362 7.
95. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 1998 32 : 496 502.
96. Allred AJ, Diz DI, Ferrario CM, Chappell MC. Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am. J. Physiol. Renal Physiol. 2000 279 : F841 50.
97. Lubel JS, Herath CB, Jia Z, Burrell LM, Angus PW. Angiotensin 1-7 reduces bile duct proliferation and hepatic fibrosis in the bile duct ligated rat. Hepatology 2007 46 (S1 A706 7.
98. Oesterreicher CH, Seki E, Mincis SD et al. Angiotensin-converting enzyme 2 is a negative regulator of chronic liver injury. Hepatology 2007 46 (S1 A298 9.
99. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am. J. Physiol. Heart. Circ. Physiol. 2005 289 : H2281 90.
100. Lubel JS, Herath CB, Warner FJ, Jia ZY, Burrell LM, Angus PW. Upregulation of the ACE2/Ang(1-7)/Mas receptor axis in the bile duct ligation (BDL) model of hepatic fibrosis does not affect hepatic sinusoidal resistance. J. Gastroenterol. Hepatol. 2006 21 (Suppl 4 A332.
101. Carvalho LT, Nascimento EA, Teixeira FO, Nagaoka MR, Borges DR, Kouyoumdjian M. Hepatic conversion of angiotensin I and the portal hypertensive response to angiotensin II in normal and regenerating liver. J. Gastroenterol. Hepatol. 2007 22 : 1543 8.
102. Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1-7)- stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001 37 : 72 6.
103. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J. Hepatol. 2007 46 : 927 34.
104. Hendrickson H, Chatterjee S, Cao S, Morales Ruiz M, Sessa WC, Shah V. Influence of caveolin on constitutively activated recombinant eNOS: insights into eNOS dysfunction in BDL rat liver. Am. J. Physiol. Gastrointest Liver Physiol. 2003 285 : G652 60.
105. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J. Cardiovasc. Pharmacol. 1990 15 : 276 82.
106. Sharman DC, Morris AD, Struthers AD. Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. Diabetologia 2007 50 : 2061 6.
107. van de Wal RM, Plokker HW, Lok DJ et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int. J. Cardiol. 2006 106 : 367 72.
108. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999 82 : 57 61.
109. Ikura Y, Ohsawa M, Shirai N et al. Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension. Hepatol. Res. 2005 32 : 107 16.
110. Ferrario CM, Jessup J, Gallagher PE et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005 68 : 2189 96.
111. Kasper SO, Basso N, Kurnjek ML et al. Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. Am. J. Nephrol. 2005 25 : 335 41.
112. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin- converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005 111 : 2605 10.
113. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998 31 (Pt 2 356 61.
114. Collister JP, Hendel MD. The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J. Renin Angiotensin Aldosterone Syst. 2003 4 : 176 9.
115. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998 31 : 699 705.
116. Iyer SN, Yamada K, Diz DI, Ferrario CM, Chappell MC. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. J. Cardiovasc. Pharmacol. 2000 36 : 109 17.
117. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004 43 : 970 6.
118. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc. Drug Rev. 2006 24 : 239 46.
119. Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem. Pharmacol. 2008 75 : 781 6.